Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22572020 | 0.81 | ALDH1A1 (0.35) | NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL15332460 | 0.78 | HSD17B10 (0.46) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL3432268 | 0.78 | NPC1 (0.36) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL22723879 | 0.76 | HTT (0.38) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL20572656 | 0.74 | NPC1 (0.35) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| Potassium Ion SCHEMBL31377889 | 0.74 | NPC1 (0.35) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL31377840 | 0.74 | SMN1; SMN2 (0.36) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| Lithium Ion SCHEMBL17726187 | 0.74 | NPC1 (0.35) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL21423701 | 0.73 | NPC1 (0.37) | NPC1RAB9AHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL12862987 | 0.73 | HDAC8 (0.48) | NPC1RAB9AKMT2AGPR88HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | NPC1 383/4885RAB9A 1502/4885CYP1A2 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.